European Journal of Cancer and Clinical Oncology
Volume 24, Issue 2, February 1988, Pages 123-129
The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16–213, doxorubicin and vincristine (VPAV) for small cell lung cancer
References (35)
- et al.
Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma
Lancet
(1980) - et al.
Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer
Eur J Cancer Clin Oncol
(1983) - et al.
False-positive ketonuria during isosfamide and mesna therapy
Eur J Cancer Clin Oncol
(1986) - et al.
Cyclic alternating ‘non-cross resistant’ chemotherapy in the management of small cell anaplastic carcinoma of the lung
Cancer Treat Rev
(1984) - et al.
Small cell lung carcinoma of the lung: the prognostic significance of stage on survival
Eur J Cancer
(1979) Chemotherapy for small cell lung cancer
Br Med J
(1985)- Vogelsang GB, Abeloff MD, Ettinger DS, Booker SV. Long term survivors of small cell carcinoma of the lung. Am J Med79,...
- et al.
Patients with small cell lung cancer treated with combination chemotherapy with or without irradiation
Ann Intern Med
(1985) - et al.
Three months treatment with chemotherapy and radiotherapy for small cell lung cancer
Br J Cancer
(1985) - et al.
Three months' treatment with cyclophosphamide, VP-16–213 followed by methotrexate and thoracic radiotherapy for small cell lung cancer
Cancer
(1985)
A randomized trial of cyclophosphamide pretreatment (‘priming’) before short-duration chemotherapy for small cell lung carcinoma
Eur J Cancer Clin Oncol
(1985)
Combined modality treatment of short duration in small cell lung cancer
Eur J Cancer Clin Oncol
(1984)
High-dose ifosfamide in advanced osteosarcoma
Cancer Treat Rep
(1985)
Ifosfamide: an active drug in the treatment of adenocarcinoma of the pancreas
J Clin Oncol
(1985)
Ifosfamide: European perspective
Semin Oncol
(1982)
Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results
Cancer Treat Rep
(1975)
Multidrug-resistance phenotype in Chinese hamster ovary cells
Cancer Treat Rep
(1983)
Cited by (41)
Combination chemotherapy with paclitaxel and ifosfamide as the third-line regimen in patients with heavily pretreated small cell lung cancer
2007, Lung CancerCitation Excerpt :Whether the sequence of the regimens used for induction chemotherapy and second-line chemotherapy truly influence the response rates to salvage chemotherapy in SCLC remains to be further evaluated in future studies. Paclitaxel and ifosfamide demonstrated activity as single agents and as part of a combination regimen for SCLC, both in first-line treatment and in the setting of relapsed/refractory disease [19,20,32–37]. The triplet combination of paclitaxel, ifosfamide and platinum analogs were evaluated in several studies.
Modulation of MDR1 and CYP3A expression by dexamethasone: Evidence for an inverse regulation in adrenals
1998, Biochemical and Biophysical Research CommunicationsSmall cell lung cancer: Biological and therapeutic aspects
1996, Critical Reviews in Oncology/Hematology
Copyright © 1988 Published by Elsevier Ltd.